In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
2023 Annual Review of Antitrust Law Developments
CRA’s Yajing Jiang contributed to Chapter 1 “Restraints of Trade” of the 2023 Annual Review of Antitrust Law Developments recently published by the ABA...